Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
NCT04215445
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Diabetic Retinopathy
Chronic Kidney Diseases
Diabetes Mellitus
Interventions
DRUG:
Empagliflozin 25 MG
DEVICE:
OCT-A
Sponsor
National University of Malaysia